Prometheus Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RXDX research report →
Companywww.prometheusbiosciences.com
Prometheus Biosciences, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.
- CEO
- Mark C. McKenna
- IPO
- 2021
- Employees
- 97
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $9.56B
- P/E
- -57.28
- P/S
- 1403.81
- P/B
- 12.01
- EV/EBITDA
- -64.04
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -2140.96%
- Net Margin
- -2081.83%
- ROE
- -31.12%
- ROIC
- -20.21%
Growth & Income
- Revenue
- $6.81M · 117.61%
- Net Income
- $-141,752,000 · -57.61%
- EPS
- $-3.49 · -21.60%
- Op Income
- $-145,778,000
- FCF YoY
- -94.86%
Performance & Tape
- 52W High
- $199.96
- 52W Low
- $23.27
- 50D MA
- $182.36
- 200D MA
- $108.85
- Beta
- -0.49
- Avg Volume
- 1.22M
Get TickerSpark's AI analysis on RXDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 23 | Hendrix Martin | sell | 40,000 |
| Jun 16, 23 | Hendrix Martin | sell | 20,500 |
| Jun 16, 23 | Hendrix Martin | sell | 2,071 |
| Jun 16, 23 | Laur James | sell | 20,500 |
| Jun 16, 23 | Laur James | sell | 2,071 |
| Jun 16, 23 | Laur James | sell | 40,000 |
| Jun 16, 23 | Stenhouse Mark | sell | 34,085 |
| Jun 16, 23 | Stenhouse Mark | sell | 40,000 |
| Jun 16, 23 | Stenhouse Mark | sell | 70,371 |
| Jun 16, 23 | Stenhouse Mark | sell | 240,000 |
Our RXDX Coverage
We haven't published any research on RXDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RXDX Report →